Gefitinib vs Ipilimumab

Gefitinib vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Gefitinib and Ipilimumab.

Mechanism of Action

Gefitinib: Selective reversible inhibitor of EGFR tyrosine kinase.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Gefitinib — 48 hours; Ipilimumab — 14.7 days.

Chemical Properties

Molecular Formula: Gefitinib — C22H24ClFN4O3.

Molecular Weight: Gefitinib — 446.9000 g/mol.

Type: Gefitinib — Small molecule; Ipilimumab — Antibody.